High Chemokine Receptor CXCR4 Level in Triple Negative Breast Cancer Specimens Predicts Poor Clinical Outcome

Journal of Surgical Research

Volumn 159, Issue 2, 2010, Pages 689-695

  Chu, Quyen D ^a   Panu, Lori ^a   Holm, Neal T ^a   Li, Benjamin D L ^a   Johnson, Lester W ^b   Zhang, Songlin ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b EA Conway Hospital   (United States)

Author keywords

chemokine receptor CXCR4; triple negative breast cancer

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADULT; ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH SURVEY; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; RISK FACTOR; STANDARD; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HELA CELLS; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CXCR4; RECURRENCE; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77949489467     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2008.09.020     Document Type: Article

References (24)

1. Perou C.M., Sørlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747
2. Sotiriou C., Neo S.Y., McShane L.M., et al. Breast cancer classification and prognosis based on gene expression profiles from a population based study. Proc Natl Acad Sci USA 100 (2003) 10393
3. Sørlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98 (2001) 10869
4. van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530
5. Rouzier R., Perou C., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 (2005) 5678
6. Carey L.A., Dees E.C., Sawyer L.R., et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Can Res 13 (2007) 2328
7. Kennedy R., Quinn J., Mullan P., et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96 (2004) 1659
8. Pinilla S., Honrado E., Hardisson D., et al. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 99 (2006) 85
9. Li H., Cherukuri P., Li N., et al. Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res 67 (2007) 501
10. Siziopikou K., and Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 16 (2007) 104
11. Hoadley K., Weigman V., Fan C., et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 8 (2007) 258
12. Moyano J., Evans J., Chen F., et al. Alpha B-Crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 116 (2006) 261
13. Chelouche-Lev D., Kluger H., Berger A., et al. Alpha B-crystallin as a marker of lymph node-involvement in breast carcinoma. Cancer 100 (2004) 2543
14. Müller A., Homey B., Soto H., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50
15. Salvucci O., Bouchard A., Baccarelli A., et al. The role of CXCR4 receptor expression in breast cancer: A large tissue microarray study. Breast Cancer Res Treat 97 (2006) 275
16. Lee B., Lee T., Avraham S., and Avraham H. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1α in breast cancer cell migration through human brain microvascular endothelial cells. Mole Cancer Res 6 (2004) 327
17. Liang Z., Yoon Y., Votaw J., et al. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 65 (2005) 967
18. Lapteva N., Yang A., Sanders D., et al. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 12 (2005) 84
19. Smith M., Luker K., Garbow J., et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64 (2004) 8604
20. Holm N., Byrnes K., Li B., Turnage R., Abreo F., Mathis J., and Chu Q.D. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. J Surg Res 141 (2007) 91
21. Holm N., Abreo F., Johnson L., Li B., and Chu Q.D. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC). Breast Cancer Res Treatment (2008) 10.1007/s10549-008-9921-8
22. Holm N., Li B., Turnage R., Johnson L., and Chu Q.D. Chemokine Receptor CXCR4 overexpression predicts recurrence for hormone-receptor positive, node-negative breast cancer patients. J Surg Res 144 (2008) 319
23. Haffty B., Yang Q., Reiss M., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Onc 24 (2006) 5652
24. Ihemelandu C., Naab T., Mezghebe H., et al. Basal cell-like (triple-negative) breast cancer, a predictor of distant metastasis in African American women. Am J Surgery 195 (2008) 153